Anika Therapeutics reports third-quarter 2014 financial results
Anika Therapeutics reported net income for the 2014 third quarter was $6.2 million, or $0.40 per diluted share versus $5.0 million, or $0.33 per diluted share, in the same 2013 quarter. Total revenue for the 2014 third quarter was $22.1 million versus $17.8 million in the same 2013 period. October 29, 2014